{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:46Z","timestamp":1740147766694,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s11739-024-03663-y","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:02:05Z","timestamp":1717182125000},"page":"329-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ceftriaxone 1\u00a0g versus 2\u00a0g per day, for the treatment of community-acquired pneumonia: a retrospective cohort study\u2014comment"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-1031","authenticated-orcid":false,"given":"Tiago","family":"Zequin\u00e3o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2208-1417","authenticated-orcid":false,"given":"Felipe Storm","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-3096","authenticated-orcid":false,"given":"Gabriel Della Torres","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4078-2046","authenticated-orcid":false,"given":"Joao Paulo","family":"Telles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3471-1786","authenticated-orcid":false,"given":"Felipe Francisco","family":"Tuon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"issue":"7","key":"3663_CR1","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s11739-023-03372-y","volume":"18","author":"D Guz","year":"2023","unstructured":"Guz D, McNeil R, Buchrits S, Goshen S, Gafter-Gvili A, Avni T (2023) Ceftriaxone 1 g versus 2 g per day, for the treatment of community-acquired pneumonia: a retrospective cohort study. Intern Emerg Med 18(7):1919\u20131927","journal-title":"Intern Emerg Med"},{"issue":"21","key":"3663_CR2","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","volume":"372","author":"RG Sawyer","year":"2015","unstructured":"Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, Cook CH, O\u2019Neill PJ, Mazuski JE, Askari R, Wilson MA, Napolitano LM, Namias N, Miller PR, Dellinger EP, Watson CM, Coimbra R, Dent DL, Lowry SF, Cocanour CS, West MA, Banton KL, Cheadle WG, Lipsett PA, Guidry CA, Popovsky K, Investigators S-IT (2015) Trial of short-course antimicrobial therapy for intra-abdominal infection. N Engl J Med 372(21):1996\u20132005","journal-title":"N Engl J Med"},{"issue":"1","key":"3663_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1186\/s12879-019-4552-8","volume":"19","author":"S Hasegawa","year":"2019","unstructured":"Hasegawa S, Sada R, Yaegashi M, Morimoto K, Mori T, G.-J. Adult Pneumonia Study (2019) 1g versus 2 g daily intravenous ceftriaxone in the treatment of community onset pneumonia - a propensity score analysis of data from a Japanese multicenter registry. BMC Infect Dis 19(1):1079","journal-title":"BMC Infect Dis"},{"issue":"7","key":"3663_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14787210.2019.1627872","volume":"17","author":"JP Telles","year":"2019","unstructured":"Telles JP, Cieslinski J, Gasparetto J, Tuon FF (2019) Efficacy of ceftriaxone 1 g daily versus 2 g daily for the treatment of community-acquired pneumonia: a systematic review with meta-analysis. Expert Rev Anti Infect Ther 17(7):501\u2013510","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"3663_CR5","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1365-2125.2011.04005.x","volume":"72","author":"D Garot","year":"2011","unstructured":"Garot D, Respaud R, Lanotte P, Simon N, Mercier E, Ehrmann S, Perrotin D, Dequin PF, Le Guellec C (2011) Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol 72(5):758\u2013767","journal-title":"Br J Clin Pharmacol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03663-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-024-03663-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03663-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T17:37:39Z","timestamp":1738690659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-024-03663-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3663"],"URL":"https:\/\/doi.org\/10.1007\/s11739-024-03663-y","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"type":"print","value":"1828-0447"},{"type":"electronic","value":"1970-9366"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethical Committee from PUCPR (CAAE: 28859719.3.0000.0020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The ethics committee for human studies waived the consent form due to the retrospective nature involving epidemiological data without therapeutic intervention or patient contact.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement, Informed consent and Consent to participate"}},{"value":"All authors approved the final version of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}